Literature DB >> 8013952

Epstein-Barr-encoded RNA in situ hybridization: diagnostic applications.

R F Ambinder1, R B Mann.   

Abstract

Latent Epstein-Barr virus (EBV) infection is associated with a variety of malignancies and other diseases. Highly restricted viral antigen expression and low viral genome copy number in infected tissues impede conventional immunohistochemical or in situ hybridization approaches to the detection of virus in these tissues. In situ hybridization detection of two small but very abundant nuclear RNAs known as the EBERs serves as an alternative approach. The EBERs are stable over time and can be detected in all common fixatives. This technique facilitates characterization of the cellular locus of latent EBV infection in histologically complex tissues, such as Hodgkin's disease and angioimmunoblastic lymphadenopathy with dysproteinemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013952     DOI: 10.1016/0046-8177(94)90227-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  24 in total

Review 1.  Molecular diagnosis of Epstein-Barr virus-related diseases.

Authors:  M L Gulley
Journal:  J Mol Diagn       Date:  2001-02       Impact factor: 5.568

2.  Nutrients and genetic variation involved in one-carbon metabolism and Hodgkin lymphoma risk: a population-based case-control study.

Authors:  Julie L Kasperzyk; Ellen T Chang; Brenda M Birmann; Peter Kraft; Tongzhang Zheng; Nancy E Mueller
Journal:  Am J Epidemiol       Date:  2011-08-01       Impact factor: 4.897

Review 3.  In situ hybridization: methods and applications.

Authors:  L Jin; R V Lloyd
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

4.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

5.  Dietary pattern and risk of hodgkin lymphoma in a population-based case-control study.

Authors:  Mara M Epstein; Ellen T Chang; Yawei Zhang; Teresa T Fung; Julie L Batista; Richard F Ambinder; Tongzhang Zheng; Nancy E Mueller; Brenda M Birmann
Journal:  Am J Epidemiol       Date:  2015-07-15       Impact factor: 4.897

6.  Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma.

Authors:  Lynn I Levin; Ellen T Chang; Richard F Ambinder; Evelyne T Lennette; Mark V Rubertone; Risa B Mann; Michael Borowitz; Edward G Weir; Susan L Abbondanzo; Nancy E Mueller
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

7.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

Authors:  R E Wilentz; M Goggins; M Redston; V A Marcus; N V Adsay; T A Sohn; S S Kadkol; C J Yeo; M Choti; M Zahurak; K Johnson; M Tascilar; G J Offerhaus; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

8.  Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy.

Authors:  Ken H Young; Dahua Zhang; Jeffery T Malik; Eliot C Williams
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  Subtype of dietary fat in relation to risk of Hodgkin lymphoma: a population-based case-control study in Connecticut and Massachusetts.

Authors:  Yongshun Gao; Qian Li; Bryan A Bassig; Ellen T Chang; Min Dai; Qin Qin; Yawei Zhang; Tongzhang Zheng
Journal:  Cancer Causes Control       Date:  2013-01-12       Impact factor: 2.506

10.  Body size and risk of Hodgkin's lymphoma by age and gender: a population-based case-control study in Connecticut and Massachusetts.

Authors:  Qian Li; Ellen T Chang; Bryan A Bassig; Min Dai; Qin Qin; Yongshun Gao; Yawei Zhang; Tongzhang Zheng
Journal:  Cancer Causes Control       Date:  2012-12-04       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.